345347-16-2

Upstream product

• 18819-89-1 tetrabutylammonium benzoate 
• 648901-43-3 (S)-1-[(R)-2-((S)-Methoxycarbonyl-trifluoromethanesulfonyloxy-methyl)-hexanoyl]-pyrrolidine-2-carboxylic acid tert-butyl ester 
• 345347-06-0 (R)-2-((S)-2,2-Dimethyl-5-oxo-[1,3]dioxolan-4-yl)-hexanoic acid 
• 345347-10-6 (S)-1-[(R)-2-((S)-2,2-Dimethyl-5-oxo-[1,3]dioxolan-4-yl)-hexanoyl]-pyrrolidine-2-carboxylic acid tert-butyl ester 
• 345347-12-8 (S)-1-[(R)-2-((S)-Hydroxy-methoxycarbonyl-methyl)-hexanoyl]-pyrrolidine-2-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

α-substituted hydroxamic acids as novel bacterial deformylase inhibitor-based antibacterial agents

We report the synthesis and biological activity of analogues of VRC3375 (N-hydroxy-3-R-butyl-3-[(2-S-(tert-butoxycarbonyl)-pyrrolidin-1-ylcarbonyl] propionamide), an orally active peptide deformylase inhibitor. This study explores the structure-activity relationship of various chelator groups, alpha substituents, P2′ and P3′ substituents in order to achieve optimal antibacterial activity with minimal toxicity liability.